Registration successful.
Account activated – Pending validation
Your account has been activated successfully, but we still need to validate you as a UK healthcare professional. We’ll send you an email with the result. Please note this could take up to 10 days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website.
What is SHINGRIX indicated for?
SHINGRIX is indicated for prevention of herpes zoster (HZ) and post-herpetic neuralgia (PHN), in:
- adults 50 years of age or older;
- adults 18 years of age or older at increased risk of HZ.1,2
SHINGRIX is formulated to help protect against shingles.1,2
Use of SHINGRIX should be in accordance with official recommendations and the Shingles National Immunisation Programme.1,2,3
SHINGRIX is contraindicated in anyone with a history of severe allergic reaction (e.g. anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX.1,2
SHINGRIX is a key component of the Shingles National Immunisation Programme and should be used with official recommendations.3
We have a range of tools to support you in implementing the Shingles National Immunisation Programme
Prescribing information (GB)
Prescribing information (NI)
Summary of product characteristics & Patient information leaflet (GB)
Summary of product characteristics & Patient information leaflet (NI)
References
- SHINGRIX. Summary of Product Characteristics (GB)
- SHINGRIX, Northern Ireland Summary of Product Characteristics (SPC)
- The GreenBook chapter 28a – Shingles. July 2023
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.
SHINGRIX is owned by or licensed to the GSK group of companies.
© 2023 GSK group of companies or its licensor.
Trade marks are owned by or licensed to the GSK group of companies.
November 2023 | PM-GB-SGX-WCNT-230008 (V2.0)
